SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

NEW YORK--(BUSINESS WIRE)--Oct 5, 2026--

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. ("“ARS Pharmaceuticals” or the “Company”) (NASDAQ: SPRY) and reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005478127/en/

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material adverse facts concerning the expected timeline for the expanded insurance coverage for neffy through CVS Caremark.

On June 24, 2026, after the market closed, ARS published a press release announcing that no new commercial formulary additions or coverage decisions had been issued for neffy in the July 1, 2026 cycle, and that CVS Caremark reserved its decision on the expanded insurance coverage for neffy until January 2027. On this news, ARS's stock price fell $2.52, or 23.9%, to close at $8.02 per share on June 25, 2026, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding ARS Pharmaceuticals’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the ARS Pharmaceuticals class action, go to www.faruqilaw.com/SPRY or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the ARS Pharmaceuticals Securities Class Action Lawsuit:

What is the ARS Pharmaceuticals securities fraud lawsuit about?

A securities class action lawsuit has been filed against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased the company's securities during the Class Period. The complaint alleges that defendants made overwhelmingly positive statements to investors while simultaneously disseminating false and misleading statements and/or concealing material adverse facts regarding the expected timeline for expanded insurance coverage of neffy through CVS Caremark. Specifically, the lawsuit alleges that defendants failed to disclose that no new commercial formulary additions or coverage decisions would be issued for neffy in the July 1, 2026 cycle, and that CVS Caremark had allegedly reserved its coverage decision until January 2027. When this information was disclosed on June 24, 2026, after market close, ARS's stock price allegedly fell $2.52, or approximately 23.9%, to close at $8.02 per share on June 25, 2026, on unusually heavy trading volume, causing significant losses to investors who had allegedly purchased shares at artificially inflated prices.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. securities traded on the NASDAQ under the ticker symbol SPRY between March 9, 2026 and June 24, 2026, inclusive, may be eligible to participate in this class action lawsuit. The lawsuit is brought on behalf of all such investors who allegedly suffered losses as a result of the conduct described in the complaint. Participation in the case is not limited to those who seek appointment as lead plaintiff — any eligible investor who purchased shares during the Class Period may potentially share in any recovery that may be obtained. Investors are encouraged to review their trading records to determine whether they purchased ARS Pharmaceuticals securities during the relevant period.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is a court-appointed representative who serves on behalf of all class members and plays an active role in directing the litigation, including working with counsel on case strategy and settlement decisions. Under the Private Securities Litigation Reform Act, any investor who purchased ARS Pharmaceuticals securities during the Class Period may move the court for appointment as lead plaintiff, and the deadline to file such a motion is October 5, 2026. Courts generally appoint the movant with the largest financial interest in the relief sought who also satisfies the requirements of Federal Rule of Civil Procedure 23. Importantly, investors are not required to seek appointment as lead plaintiff in order to participate in the lawsuit or share in any recovery that may result from the litigation.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased ARS Pharmaceuticals securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

ARLINGTON, Va. (AP) — Alex Ovechkin said Monday that his 22nd season in the NHL will be his last, beginning the farewell tour for the longtime Washington Capitals captain who holds the league's career goal-scoring record.

Ovechkin addressed teammates to deliver the news before the team posted a message from him on social media.

“It’s sad, but it is what it is,” Ovechkin said in his locker room address. “It’s hard, but let’s enjoy it and let’s do some special things this year.”

Ovechkin signed a one-year contract this past summer and turned 41 on Sept. 17. All signs pointed to this being the end, and he said he and his family decided as much in recent months.

“I love this game so much, but I know in my heart it's the right decision,” the Russian star said in a statement released before the Capitals' home opener Wednesday night.

Ovechkin broke Wayne Gretzky's goals record in April 2025 and entered this season at 929. The front office acquired Jordan Kyrou and Alex Tuch in trades and signed fellow forward Boone Jenner and defenseman Vincent Desharnais in free agency to add around a young core in the hopes of making another long playoff run and contending for the Stanley Cup.

“We have an unbelievable team this year,” Ovechkin said. “Let’s make the playoffs, let’s have fun and enjoy the moment because times fly.”

Ovechkin has spent his entire career with Washington, winning the Calder Trophy as rookie of the year in 2005-06, the Hart Trophy as MVP three times and leading the NHL in scoring nine times. He was playoff MVP in 2018 when he led the Caps to the first Stanley Cup championship in franchise history.

There's been speculation Ovechkin could receive an unfriendly reception on the road after he appeared in an ad for a party aligned with Vladimir Putin during the offseason. But there wasn't much sign of that during the first two games of the season — at Carolina and at Tampa Bay.

When addressing the fallout from that last month, Ovechkin confirmed he'd be going back to live in Russia when he retired from the NHL.

In Washington's season-opening win over the Hurricanes, Ovechkin had 12 minutes, 46 seconds of ice time, the lowest of his career in a game when he wasn't injured or ejected.

The Capitals missed the playoffs in 2025-26, but Ovechkin played all 82 games and scored 32 goals. He’s reached 30 in every season of his career except 2020-21, when he played only 45 games.

Long before he broke through during the Capitals’ Stanley Cup run, Ovechkin had rejuvenated hockey in Washington, and he’ll retire as one of the city’s most accomplished athletes in any sport. The Capitals drafted him No. 1 overall in 2004, and he and Pittsburgh’s Sidney Crosby became stars almost immediately in 2005 when the league emerged from missing a season because of a lockout.

Ovechkin’s combination of goal-scoring skill, physicality and boundless energy made him an instant hit, and he scored a career-high 65 goals in his third season, which earned him the first of his Hart Trophies.

Washington’s penchant for postseason heartache, which existed long before Ovechkin showed up, followed him for a while as well. The Capitals won the Presidents’ Trophy three times with the league’s best regular-season record, falling short in the playoffs each time before a Washington team that merely won its division finally went all the way in the playoffs.

In four postseason meetings between Crosby and Ovechkin — in 2009, 2016, 2017, 2018 — the winner won the Stanley Cup each time. Washington's home opener Wednesday is against Pittsburgh.

See AP’s full NHL coverage here

Carolina Hurricanes' Jaccob Slavin (74) defends against Washington Capitals' Alex Ovechkin (8) during the third period of an NHL hockey game in Raleigh, N.C., Friday, Oct. 2, 2026. (AP Photo/Karl DeBlaker)

Washington Capitals left wing Alex Ovechkin (8) handles the puck during the third period of an NHL hockey game against the Tampa Bay Lightning Saturday, Oct. 3, 2026, in Tampa, Fla. (AP Photo/Jason Behnken)

Washington Capitals left wing Alex Ovechkin (8) looks to shoot against Tampa Bay Lightning goaltender Andrei Vasilevskiy (88) and defenseman Victor Hedman (77) during the third period of an NHL hockey game Saturday, Oct. 3, 2026, in Tampa, Fla. (AP Photo/Jason Behnken)

Washington Capitals' Alex Ovechkin watches the puck during the first period of an NHL hockey game against the Carolina Hurricanes in Raleigh, N.C., Friday, Oct. 2, 2026. (AP Photo/Karl DeBlaker)